MX374539B - [1,2,4]triazolo[4,3-b]piridazinas para uso en el tratamiento de enfermedades proliferativas. - Google Patents

[1,2,4]triazolo[4,3-b]piridazinas para uso en el tratamiento de enfermedades proliferativas.

Info

Publication number
MX374539B
MX374539B MX2017001218A MX2017001218A MX374539B MX 374539 B MX374539 B MX 374539B MX 2017001218 A MX2017001218 A MX 2017001218A MX 2017001218 A MX2017001218 A MX 2017001218A MX 374539 B MX374539 B MX 374539B
Authority
MX
Mexico
Prior art keywords
sup
pyridazines
triazolo
treatment
proliferative diseases
Prior art date
Application number
MX2017001218A
Other languages
English (en)
Spanish (es)
Other versions
MX2017001218A (es
Inventor
Alfred Arthur Rabow
Arshed Mahmood
James Francis Mccabe
Michael James Waring
Robert Hugh Bradbury
Steven Christopher Glossop
Zoe Ann Cotter
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2017001218A publication Critical patent/MX2017001218A/es
Publication of MX374539B publication Critical patent/MX374539B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • E—FIXED CONSTRUCTIONS
    • E21—EARTH OR ROCK DRILLING; MINING
    • E21B—EARTH OR ROCK DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
    • E21B7/00—Special methods or apparatus for drilling
    • E21B7/04—Directional drilling
    • E21B7/06—Deflecting the direction of boreholes
    • E—FIXED CONSTRUCTIONS
    • E21—EARTH OR ROCK DRILLING; MINING
    • E21B—EARTH OR ROCK DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
    • E21B7/00—Special methods or apparatus for drilling
    • E21B7/04—Directional drilling
    • E21B7/06—Deflecting the direction of boreholes
    • E21B7/062—Deflecting the direction of boreholes the tool shaft rotating inside a non-rotating guide travelling with the shaft
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Geology (AREA)
  • Mining & Mineral Resources (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Environmental & Geological Engineering (AREA)
  • Fluid Mechanics (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Geochemistry & Mineralogy (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2017001218A 2014-07-28 2015-07-24 [1,2,4]triazolo[4,3-b]piridazinas para uso en el tratamiento de enfermedades proliferativas. MX374539B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462029676P 2014-07-28 2014-07-28
PCT/GB2015/052143 WO2016016618A1 (en) 2014-07-28 2015-07-24 [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases

Publications (2)

Publication Number Publication Date
MX2017001218A MX2017001218A (es) 2017-05-01
MX374539B true MX374539B (es) 2025-03-06

Family

ID=53761420

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001218A MX374539B (es) 2014-07-28 2015-07-24 [1,2,4]triazolo[4,3-b]piridazinas para uso en el tratamiento de enfermedades proliferativas.

Country Status (37)

Country Link
US (5) US9944650B2 (enExample)
EP (1) EP3174881B1 (enExample)
JP (1) JP6592503B2 (enExample)
KR (1) KR20170033427A (enExample)
CN (1) CN106536524B (enExample)
AP (1) AP2017009700A0 (enExample)
AU (1) AU2015295120B2 (enExample)
BR (1) BR112017001160A2 (enExample)
CA (2) CA2956421C (enExample)
CL (1) CL2017000223A1 (enExample)
CO (1) CO2017001918A2 (enExample)
CY (1) CY1120602T1 (enExample)
DK (1) DK3174881T3 (enExample)
DO (1) DOP2017000018A (enExample)
EA (1) EA032654B9 (enExample)
ES (1) ES2670444T3 (enExample)
GT (1) GT201700016A (enExample)
HR (1) HRP20180788T1 (enExample)
HU (1) HUE037571T2 (enExample)
IL (1) IL250104B (enExample)
LT (1) LT3174881T (enExample)
MX (1) MX374539B (enExample)
MY (1) MY187251A (enExample)
NI (1) NI201700006A (enExample)
NO (2) NO2719005T3 (enExample)
PE (1) PE20170527A1 (enExample)
PH (1) PH12017500159B1 (enExample)
PL (1) PL3174881T3 (enExample)
PT (1) PT3174881T (enExample)
RS (1) RS57242B1 (enExample)
SG (1) SG11201700419SA (enExample)
SI (1) SI3174881T1 (enExample)
SM (1) SMT201800260T1 (enExample)
SV (1) SV2017005368A (enExample)
TN (1) TN2017000018A1 (enExample)
WO (1) WO2016016618A1 (enExample)
ZA (1) ZA201701207B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2719005T3 (enExample) * 2014-07-28 2018-01-20
CN110317216A (zh) * 2018-03-28 2019-10-11 首都医科大学 一种三唑并哒嗪类衍生物在医药领域的应用
TWI816880B (zh) * 2018-09-13 2023-10-01 大陸商恒翼生物醫藥（上海）股份有限公司 治療前列腺癌之組合療法
MX2022004555A (es) 2019-10-14 2022-07-21 Astrazeneca Ab Terapia de combinacion para tratar una neoplasia maligna hematologica.
JP2023509191A (ja) 2020-01-09 2023-03-07 アストラゼネカ・アクチエボラーグ 癌を治療するための組み合わせ療法
CN113143930B (zh) * 2021-04-08 2023-05-30 深圳湾实验室 化合物在制备SARS-Cov-2 E蛋白抑制剂中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795273B2 (en) 2005-12-08 2010-09-14 Novartis Ag Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors
GB0525065D0 (en) * 2005-12-08 2006-01-18 Novartis Ag Organic compounds
CN101952286A (zh) 2007-12-21 2011-01-19 阿斯利康(瑞典)有限公司 用于治疗和雄激素受体有关的病症的双环衍生物
WO2010092371A1 (en) * 2009-02-10 2010-08-19 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
EP2430024A1 (en) * 2009-05-11 2012-03-21 AstraZeneca AB [1,2,4]triazolo [4,3-b]pyridazines as ligands of the androgen receptor
CA2779355C (en) 2009-11-05 2018-01-16 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
WO2012174487A2 (en) * 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9422290B2 (en) 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
NO2719005T3 (enExample) * 2014-07-28 2018-01-20

Also Published As

Publication number Publication date
MY187251A (en) 2021-09-15
KR20170033427A (ko) 2017-03-24
AU2015295120A8 (en) 2017-02-09
EA032654B1 (ru) 2019-06-28
SI3174881T1 (en) 2018-06-29
EP3174881B1 (en) 2018-03-28
AP2017009700A0 (en) 2017-01-31
PH12017500159A1 (en) 2017-07-10
IL250104A0 (en) 2017-03-30
PH12017500159B1 (en) 2020-12-09
US9944650B2 (en) 2018-04-17
NI201700006A (es) 2017-08-25
HUE037571T2 (hu) 2018-09-28
NO3174881T3 (enExample) 2018-08-25
PT3174881T (pt) 2018-05-25
ES2670444T3 (es) 2018-05-30
US11407755B2 (en) 2022-08-09
JP6592503B2 (ja) 2019-10-16
JP2017522338A (ja) 2017-08-10
SMT201800260T1 (it) 2018-07-17
US20200055861A1 (en) 2020-02-20
SG11201700419SA (en) 2017-02-27
US10407432B2 (en) 2019-09-10
EA201790179A1 (ru) 2017-07-31
AU2015295120A1 (en) 2017-02-02
SV2017005368A (es) 2017-05-12
CY1120602T1 (el) 2019-12-11
CN106536524A (zh) 2017-03-22
DOP2017000018A (es) 2017-03-15
ZA201701207B (en) 2018-12-19
LT3174881T (lt) 2018-06-11
CO2017001918A2 (es) 2017-05-10
BR112017001160A2 (pt) 2017-11-14
DK3174881T3 (en) 2018-06-06
US20180230158A1 (en) 2018-08-16
WO2016016618A1 (en) 2016-02-04
GT201700016A (es) 2018-12-19
MX2017001218A (es) 2017-05-01
PE20170527A1 (es) 2017-05-24
US20170210747A1 (en) 2017-07-27
EP3174881A1 (en) 2017-06-07
IL250104B (en) 2018-10-31
EA032654B9 (ru) 2019-07-31
CL2017000223A1 (es) 2017-08-25
CA2956421C (en) 2023-03-14
CA3185741A1 (en) 2016-02-04
TN2017000018A1 (en) 2018-07-04
US10766905B2 (en) 2020-09-08
AU2015295120B2 (en) 2018-02-01
PL3174881T3 (pl) 2018-08-31
US20210107905A1 (en) 2021-04-15
RS57242B1 (sr) 2018-07-31
US20230035133A1 (en) 2023-02-02
HRP20180788T1 (hr) 2018-06-29
NO2719005T3 (enExample) 2018-01-20
CA2956421A1 (en) 2016-02-04
CN106536524B (zh) 2019-11-15

Similar Documents

Publication Publication Date Title
MX384948B (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos.
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
DOP2015000274A (es) Compuestos químicos
PH12017500367A1 (en) Compounds that inhibit mcl-1 protein
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
MX392130B (es) Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades.
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
WO2015153959A3 (en) Small molecule inhibitors of mcl-1 and uses thereof
CL2018001171A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CL2016003214A1 (es) Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
TN2015000313A1 (en) Chemical compounds
TW201613864A (en) Novel compounds
PH12017500159B1 (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
CL2018000783A1 (es) Nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen
EA201790949A1 (ru) Замещенные 2,4-диаминохинолины в качестве новых противораковых средств
UY35359A (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO
MX2016014859A (es) Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2016001024A1 (es) Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades.
CL2018002848A1 (es) Formulaciones liquidas de fosfoplatino
EA201790795A1 (ru) СОЕДИНЕНИЯ 4Н-ПИРИДО[1,2-a]ПИРИМИДИН-4-ОНА
MX360040B (es) Nuevo agente antibacteriano derivado de florfenicol unido a sulfoximina y el uso del mismo en el tratamiento de infecciones bacterianas en ganado vacuno.
UY37316A (es) Dispersión sólida farmacéutica de un inhibidor de bcl-2, composiciones farmacéuticas de ésta, y usos para el tratamiento de cáncer

Legal Events

Date Code Title Description
FG Grant or registration